Efficacy News and Research

RSS
Icahn School of Medicine receives $2.7M to investigate narrow pathway targeted immune therapy

Icahn School of Medicine receives $2.7M to investigate narrow pathway targeted immune therapy

EMA grants accelerated assessment to Boehringer Ingelheim's Faldaprevir compound

EMA grants accelerated assessment to Boehringer Ingelheim's Faldaprevir compound

Sacral neuromodulation stands test of time in LUTD

Sacral neuromodulation stands test of time in LUTD

DSMB reviews safety data from Phase I/IIa clinical trial of NTCELL for Parkinson’s disease

DSMB reviews safety data from Phase I/IIa clinical trial of NTCELL for Parkinson’s disease

FDA approves OLYSIO (simeprevir) for treatment of chronic hepatitis C infection

FDA approves OLYSIO (simeprevir) for treatment of chronic hepatitis C infection

Research paves way towards personalized chronotherapy treatments

Research paves way towards personalized chronotherapy treatments

MEMREHAB Trial shows significant effect for cognitive rehabilitation in MS

MEMREHAB Trial shows significant effect for cognitive rehabilitation in MS

Probe to measure immune function could lead to determine nanoparticle-based drugs for cancer patients

Probe to measure immune function could lead to determine nanoparticle-based drugs for cancer patients

Using radiation models to improve cancer therapies: an interview with Adrian Treverton, COO of Xstrahl and Jean-Pierre Wery, President of Crown Bioscience

Using radiation models to improve cancer therapies: an interview with Adrian Treverton, COO of Xstrahl and Jean-Pierre Wery, President of Crown Bioscience

BioCardia reports positive results for Transendocardial Autologous Cells in Ischemic Heart Failure Trial

BioCardia reports positive results for Transendocardial Autologous Cells in Ischemic Heart Failure Trial

Gene-based method for selecting doses of warfarin no better than standardized dosing methods

Gene-based method for selecting doses of warfarin no better than standardized dosing methods

Tasquinimod drug effective for men with metastatic castration-resistant prostate cancer

Tasquinimod drug effective for men with metastatic castration-resistant prostate cancer

First patients enrolled in EF-21 Study of NovoTTF Therapy for brain metastases from NSCLC cancer

First patients enrolled in EF-21 Study of NovoTTF Therapy for brain metastases from NSCLC cancer

Once-daily edoxaban prevents stroke in patients with atrial fibrillation

Once-daily edoxaban prevents stroke in patients with atrial fibrillation

Brain signals in fibromyalgia patients: an interview with Dr. Marco Loggia from Massachusetts General Hospital and Harvard Medical School in Boston

Brain signals in fibromyalgia patients: an interview with Dr. Marco Loggia from Massachusetts General Hospital and Harvard Medical School in Boston

Heart failure patients receiving LVAD may benefit from injection of powerful cells directly into heart

Heart failure patients receiving LVAD may benefit from injection of powerful cells directly into heart

Researchers study safety of transendocardial stem cell injection in patients with ischemic cardiomyopathy

Researchers study safety of transendocardial stem cell injection in patients with ischemic cardiomyopathy

KLOX receives CE mark approval in Europe for non-invasive acne vulgaris treatment

KLOX receives CE mark approval in Europe for non-invasive acne vulgaris treatment

Boston Scientific gets CE Mark approval for Vercise Deep Brain Stimulation System

Boston Scientific gets CE Mark approval for Vercise Deep Brain Stimulation System

Study: Use of bone marrow mononuclear stem cells does not improve heart function

Study: Use of bone marrow mononuclear stem cells does not improve heart function

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.